GlassScriptPhysician profile
Christina E Sawires
NPI 1487182911
$1,762.88
in general payments reported to CMS, 2019-2025
20 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $461 · 2023: $187 · 2024: $337 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $362.76 | 2021-2025 | Collagenase Santyl, Stravix Pl, Grafix Pl |
| Stryker Corporation | $278.78 | 2022-2023 | 7 X 23mm Citrelock Implant |
| Paratek Pharmaceuticals, INC. | $257.60 | 2021-2025 | Nuzyra |
| Organogenesis INC. | $228.03 | 2021-2025 | Apligraf, Puraply, Puraply Wound Matrix |
| Treace Medical Concepts, INC. | $153.22 | 2021 | |
| Kerecis Limited | $118.77 | 2022-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Integra Lifesciences Corporation | $71.68 | 2022-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Phathom Pharmaceuticals, INC. | $40.68 | 2024-2025 | Voquezna |
| Musculoskeletal Transplant Foundation INC. | $38.95 | 2021-2022 | |
| Bone Support INC. | $29.37 | 2024 | Cerament G, Ceramentbone Void Filler |
| Nabriva Therapeutics, Plc | $28.08 | 2021-2022 | |
| Lilly USA, LLC | $27.57 | 2022 | |
| Medshape, INC. | $27.41 | 2023 | Dynanail Helix, Washer, 15 Mm |
| Advanced Oxygen Therapy INC. | $17.10 | 2024 | Topical Oxygen Chamber For Extremities |
| Merck Sharp & Dohme LLC | $15.86 | 2025 | Capvaxive, Gardasil 9 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $14.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.51 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.30 | 2024 | Xifaxan |
| Cequr Corporation | $11.63 | 2024 | Cequr Simplicity |
| Paragon 28, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Sawires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.